BioMarin Pharmaceutical (NASDAQ:BMRN) EVP Gregory Friberg Sells 3,281 Shares of Stock

Posted by Brenda Bartman on May 12th, 2026

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Get Free Report) EVP Gregory Friberg sold 3,281 shares of the business’s stock in a transaction that occurred on Thursday, May 7th. The stock was sold at an average price of $53.85, for a total value of $176,681.85. Following the sale, the executive vice president directly owned 51,818 shares in the company, valued at $2,790,399.30. The trade was a 5.95% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

BioMarin Pharmaceutical Price Performance

NASDAQ:BMRN opened at $52.58 on Tuesday. The firm has a market capitalization of $10.16 billion, a price-to-earnings ratio of 38.38, a PEG ratio of 0.40 and a beta of 0.23. The company has a debt-to-equity ratio of 0.23, a current ratio of 5.81 and a quick ratio of 4.20. The business has a 50 day simple moving average of $56.06 and a 200-day simple moving average of $56.33. BioMarin Pharmaceutical Inc. has a 1 year low of $50.76 and a 1 year high of $66.28.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. PNC Financial Services Group Inc. lifted its holdings in BioMarin Pharmaceutical by 5.2% during the 1st quarter. PNC Financial Services Group Inc. now owns 14,589 shares of the biotechnology company’s stock valued at $824,000 after buying an additional 719 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in BioMarin Pharmaceutical by 14.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 3,802,930 shares of the biotechnology company’s stock worth $214,804,000 after acquiring an additional 481,176 shares in the last quarter. Parallel Advisors LLC increased its position in shares of BioMarin Pharmaceutical by 33.9% during the first quarter. Parallel Advisors LLC now owns 1,768 shares of the biotechnology company’s stock worth $100,000 after acquiring an additional 448 shares during the period. SEB Asset Management AB purchased a new position in shares of BioMarin Pharmaceutical during the first quarter worth approximately $16,567,000. Finally, Swiss National Bank raised its stake in shares of BioMarin Pharmaceutical by 0.4% during the first quarter. Swiss National Bank now owns 361,100 shares of the biotechnology company’s stock valued at $20,399,000 after acquiring an additional 1,500 shares in the last quarter. 98.71% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research analysts have weighed in on the stock. Royal Bank Of Canada reiterated a “sector perform” rating and set a $66.00 price objective on shares of BioMarin Pharmaceutical in a research report on Tuesday, May 5th. Wolfe Research restated an “outperform” rating on shares of BioMarin Pharmaceutical in a report on Monday, March 16th. Stifel Nicolaus set a $68.00 price target on shares of BioMarin Pharmaceutical in a report on Tuesday, February 24th. Canaccord Genuity Group increased their price objective on shares of BioMarin Pharmaceutical from $104.00 to $116.00 and gave the stock a “buy” rating in a research report on Thursday, May 7th. Finally, Weiss Ratings raised shares of BioMarin Pharmaceutical from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Friday, May 1st. One analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and seven have assigned a Hold rating to the company’s stock. According to data from MarketBeat, BioMarin Pharmaceutical has a consensus rating of “Moderate Buy” and an average target price of $89.91.

Read Our Latest Analysis on BMRN

BioMarin Pharmaceutical Company Profile

(Get Free Report)

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.